Elanco Animal Health (NYSE:ELAN) Releases Q2 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.170-0.210 for the period, compared to the consensus earnings per share estimate of 0.250. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Elanco Animal Health Stock Performance

NYSE ELAN traded up $0.89 on Monday, hitting $12.85. 3,580,606 shares of the company traded hands, compared to its average volume of 4,982,134. The business's 50 day moving average price is $9.89 and its 200-day moving average price is $11.42. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $18.80. The company has a market capitalization of $6.38 billion, a price-to-earnings ratio of 32.11, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.34 earnings per share. Equities analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Stifel Nicolaus boosted their price target on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday. Morgan Stanley dropped their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler decreased their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. UBS Group reduced their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Barclays lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has an average rating of "Hold" and a consensus price target of $15.00.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the purchase, the director now owns 101,459 shares in the company, valued at $1,105,903.10. The trade was a 10.93% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.89% of the stock is owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.